Adolescent BCG revaccination induces a phenotypic shift in CD4+ T cell responses to Mycobacterium tuberculosis

Nat Commun. 2024 Jun 18;15(1):5191. doi: 10.1038/s41467-024-49050-1.

Abstract

A recent clinical trial demonstrated that Bacille Calmette-Guérin (BCG) revaccination of adolescents reduced the risk of sustained infection with Mycobacterium tuberculosis (M.tb). In a companion phase 1b trial, HVTN 602/Aeras A-042, we characterize in-depth the cellular responses to BCG revaccination or to a H4:IC31 vaccine boost to identify T cell subsets that could be responsible for the protection observed. High-dimensional clustering analysis of cells profiled using a 26-color flow cytometric panel show marked increases in five effector memory CD4+ T cell subpopulations (TEM) after BCG revaccination, two of which are highly polyfunctional. CITE-Seq single-cell analysis shows that the activated subsets include an abundant cluster of Th1 cells with migratory potential. Additionally, a small cluster of Th17 TEM cells induced by BCG revaccination expresses high levels of CD103; these may represent recirculating tissue-resident memory cells that could provide pulmonary immune protection. Together, these results identify unique populations of CD4+ T cells with potential to be immune correlates of protection conferred by BCG revaccination.

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • Adolescent
  • BCG Vaccine* / immunology
  • CD4-Positive T-Lymphocytes* / immunology
  • Female
  • Humans
  • Immunization, Secondary
  • Immunologic Memory / immunology
  • Male
  • Mycobacterium tuberculosis* / immunology
  • Phenotype
  • Single-Cell Analysis
  • Th1 Cells / immunology
  • Tuberculosis / immunology
  • Tuberculosis / microbiology
  • Tuberculosis / prevention & control

Substances

  • BCG Vaccine